Greater than 95% success with 14-day bismuth quadruple anti- helicobacter pylori therapy: A pilot study in us hispanics

Helicobacter

Volumn 17, Issue 5, 2012, Pages 382-390

  Salazar, Cesar O ^a   Cardenas, Victor M ^a   Reddy, Rita K ^b   Dominguez, Delfina C ^c   Snyder, Lindsey K ^a   Graham, David Y ^b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS AT EL PASO   (United States)

Author keywords

Anti Helicobacter pylori; Bismuth; Clinical trials; Helicobacter pylori; Hispanic Americans; Metronidazole; Quadruple therapy; Treatment outcome

Indexed keywords

HELIDAC; METRONIDAZOLE; OMEPRAZOLE; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM CULTURE; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG WITHDRAWAL; FATIGUE; FECES COLOR; FEMALE; GRAM STAINING; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISPANIC; HUMAN; MALE; METALLIC TASTE; NAUSEA; NAUSEA AND VOMITING; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; TASTE DISORDER; TREATMENT DURATION; UNITED STATES; UREA BREATH TEST;

HELICOBACTER PYLORI;

EID: 84866274709     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2012.00962.x     Document Type: Article

References (49)

1. Malfertheiner P, Megraud F, O'Morain C, et al. Management of Helicobacter pylori infection - The Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
2. Cardenas VM, Prieto-Jimenez CA, Mulla ZD, Rivera JO, Dominguez DC, Graham DY, Ortiz M. Helicobacter pylori eradication and change in markers of iron stores among non-iron-deficient children in El Paso, Texas: An etiologic intervention study. J Pediatr Gastroenterol Nutr 2011;52:326-32.
3. Cardenas VM, Mulla ZD, Ortiz M, Graham DY. Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol 2006;163:127-34.
4. Epplein M, Signorello LB, Zheng W, Cai Q, Hargreaves MK, Michel A, Pawlita A, Fowke JH, Correa P, Blot WJ. Helicobacter pylori prevalence and circulating micronutrient levels in a low-income United States population. Cancer Prev Res 2011;4:871-8.
5. Wu X, Chen VW, Andrews PA, Ruiz B, Correa P. Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States: subsite and histology differences. Cancer Causes Control 2007;18:585-93.
6. Feinstein LB, Holman RC, Yorita-Christensen KL, Steiner CA, Swerdlow DL. Trends in hospitalizations for peptic ulcer disease, United States, 1998-2005. Emerg Infect Dis 2010;16:1410-8.
7. U.S. Census Bureau, 2010 American Community Survey. 2010 American Community Survey 1-Year Estimates. S0506 Selected Characteristics of the Foreign-Born Population by region of birth: Latin America. (http://factfinder2.census.gov/). (Accessed November 2011).
8. Dehesa-Violante M. Treatment of Helicobacter pylori infection. Whom to treat and with what?. Rev Gastroenterol Mex 2000;65:50-5.
9. Graham DY. Helicobacter pylori eradication therapy research: ethical issues and description of results. Clin Gastroenterol Hepatol 2010;8:1032-6.
10. Graham DY, Rimbara E. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J Clin Gastroenterol 2011;45:309-13.
11. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8.
12. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003;9:562-7.
13. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F, Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377:905-13.
14. Fischbach LA, Van Zanten SV, Dickason J. Meta-analysis: the efficacy, adverse events and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82.
15. Graham DY, Lew GM, Evans DG, et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med 1991;115:266-9.
16. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, Malaty HM. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992;116:705-8.
17. Graham DY, Hoffman J, el-Zimaity HM, Graham DP, Osato M. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11:935-8.
18. Graham DY, Belson G, Abudayyeh S, Osato MS, Dore MP, El-Zimaity HM. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis 2004;36:384-7.
19. Graham DY, Opekun AR, Belson G, El-Zimaity HM, Carlson MR. Novel bismuth-metronidazole-tetracycline triple layer tablet for treatment of Helicobacter pylori. Aliment Pharmacol Ther 2005;21:165-8.
20. Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010;15:38-45.
21. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol 2009;7:145-8.
22. Opekun AR, Luu P, Gotschall AB, Abdalla N, Torres E, Rudd SB, Graham DY, Nurgalieva ZZ, Tsuchiya K. Point-of-care Helicobacter pylori urine antibody detection in a multi-ethnic adult population in the United States. Transl Res 2006;148:13-8.
23. 13C-urea breath test for detection of Helicobacter pylori infection. Am J Gastroenterol 2001;96:1741-5.
24. Goldman J, Conrad DF, Ley C, Halperin D, de la Luz Sanchez M, Villacorta R, Parsonnet J. Validation of Spanish language dyspepsia questionnaire. Dig Dis Sci 2002;47:624-40.
25. Graham DY, Kudo M, Reddy R, Opekun AR. Practical rapid, minimally invasive, reliable nonendoscopic method to obtain Helicobacter pylori for culture. Helicobacter 2005;10:1-3.
26. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001;161:1217-20.
27. Kim JJ, Reddy R, Lee M, et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001;47:459-61.
28. Rosner B. Fundamentals of Biostatistics, 7th edn. Boston, MA: Brooks/Cole CENGAGE Learning, 2011.
29. Dean AG, Dean JA, Coulombier D, Brendel KA, Smith DC, Burton AH, Dicker RC, Sullivan K, Fagan RF, Arner TB. Epi Info, 3.5.3. A word processing, database, and statistics program for public health on IBM-compatible microcomputers. Atlanta, Georgia, USA: Centers for Disease Control and Prevention, 1996.
30. Calvet X, Gisbert JP, Suarez D. Key points for designing and reporting Helicobacter pylori therapeutic trials: a personal view. Helicobacter 2011;16:346-55.
31. Mostaghni AA, Afraid M, Eghbali S, Kumar P. Evaluation of brushing cytology in the diagnosis of Helicobacter pylori gastritis. Acta Cytol 2008;52:597-601.
32. Goel N, Sherwal BL, Patwari AK, Bajaj P, Choudhury M. Evaluation of invasive and non-invasive diagnostic modalities for Helicobacter pylori infection in children. Indian Pediatr 2003;40:141-6.
33. Ahluwalia C, Jain M, Mehta G, Kumar N. Comparison of endoscopic brush cytology with biopsy for detection of Helicobacter pylori in patients with gastroduodenal diseases. Indian J Pathol Microbiol 2001;44:283-8.
34. Patwari AK, Malhotra V, Balani B, Gangil A, Jain A, Kapoor G. Brush cytology: an adjunct to diagnostic upper GI endoscopy. Indian J Pediatr 2001;68:515-8.
35. Gomes CAR, Catapani WR, Mader AM, Locatelli A, Silva CB, Waisberg J. Antral exfoliative cytology for the detection of Helicobacter pylori in the stomach. World J Gastroenterol 2005;11:2784-8.
36. Custodio RO, Daher RR, Ximenes YR, Silvério Ade O, Custódio NR. Helicobacter pylori identification by brush gastric cytology: a comparison with histologic method. Rev Soc Bras Med Trop 2005;38:322-5.
37. De Francesco F, Nicotina PA, Picciotto M, Martines F, Ferlazzo G, d'Aquino A. Helicobacter pylori in gastroduodenal diseases: rapid identification by endoscopic brush cytology. Diagn Cytopathol 1993;9:430-3.
38. Saksena S, Dasarathy S, Verma K, Ahuja V, Sharma MP. Evaluation of endoscopy-based diagnostic methods for the detection of Helicobacter pylori. Indian J Gastroenterol 2000;19:61-3.
39. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319:670-4.
40. Lachin JM. Statistical consideration in the Intent-to-treat principle. Control Clin Trials 2000;21:167-89.
41. Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther 1995;57:6-15.
42. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Alpert LC, Genta RM. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493-6.
43. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011;378:507-14.
44. Bojalil R, Calva JJ, Ortega H. The use of antibiotics in a community of Mexico City. I. A household survey. Bol Med Hosp Infant Mex 1993;50:79-87.
45. Torres J, Camorlinga-Ponce M, Pérez-Pérez G, Madrazo-De la Garza A, Dehesa M, González-Valencia G, Muñoz O. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 2001;39:2677-80.
46. Chihu L, Ayala G, Mohar A, Hernández A, Herrera-Goepfert R, Fierros G, González-Márquez H, Silva J. Antimicrobial resistance and characterization of Helicobacter pylori strains isolated from Mexican adults with clinical outcome. J Chemother 2005;17:270-6.
47. Garza-González E, Pérez-Pérez GI, Alanís-Aguilar O, Tijerina-Menchaca R, Maldonado-Garza HJ, Bosques-Padilla FJ. Antibiotic susceptibility patterns of Helicobacter pylori strains isolated from northeastern Mexico. J Chemother 2002;14:342-5.
48. Morales TG, Sampliner RE, Camargo E, Marquis S, Garewal HS, Fennerty MB. Inability to noninvasively diagnose gastric intestinal metaplasia in Hispanics or reverse the lesion with Helicobacter pylori eradication. J Clin Gastroenterol 2001;32:400-4.
49. Prieto-Jimenez CA, Cardenas VM, Fischbach LA, Mulla ZD, Rivera JO, Dominguez DC, Graham DY, Ortiz M. Double-Blind Randomized Trial of Quadruple Sequential H. pylori Eradication Therapy in Asymptomatic, Infected Children in El Paso, Texas. J Pediatr Gastroenterol Nutr 2011;52:319-25.